Radar Therapeutics is at the forefront of developing precision-expressed mRNA-based therapeutics, which represent a novel approach in the field of genetic medicine. The company utilizes advanced techniques in synthetic biology, leveraging single-cell transcriptomic data and RNA-editing enzymes to create "smart" mRNAs. These mRNAs are designed to read the cellular environment in real-time, allowing for precise reprogramming of targeted cells at the right moment. This capability aims to enhance the specificity of treatments, minimizing potential toxic side effects associated with non-targeted therapies.

The RADAR platform developed by Radar Therapeutics enables controlled and timely reading of mRNA messages, facilitating the safe delivery of genetically encoded therapies. This technology not only allows for scalable in vivo reprogramming, which reduces the costs and risks associated with ex vivo treatments, but also provides a universal mechanism to interpret the RNA profiles that dictate individual cell behavior. By harnessing these innovative approaches, Radar Therapeutics aims to advance a new class of safe and effective medicines, paving the way for breakthroughs in precision medicine.

United States

Radar Therapeutics is a biotech company developing programmable precision therapeutics using molecular RNA sensors. The company has raised $13.4 million in seed funding to support its work in developing smart, programmable medicines. Radar Therapeutics is also the winner of the first-ever Amgen Bakar Labs Diversity, Inclusion, and Belonging Award. The company is building a business around medicines that use RNA sensors—mRNAs that gate their expression based on other RNAs in the cell.

Radar Therapeutics

Company Details